Literature DB >> 1155732

Problems with bovine heterografts for hemodialysis. Recognition, correction, and prevention.

J J Rosental, A Spigelman, M R Gaspar, H J Movius.   

Abstract

1. Careful examination of the peripheral blood vessels is essential in choosing the site for an arteriovenous heterograft. 2. Ischemia of the hand or fingers was avoided by placing upper extremity grafts in the forearm. 3. In the lower extremity, if peripheral pulses are normal, a straight thigh graft is preferred. 4. The recipient vien in the antecubital fossa should be no less than 4 mm in diameter; in the lower extremity the venous anastomosis should be made to the common femoral vein. 5. "Graft hypertension" is a sign of inadequate venous runoff and should be corrected before false aneurysms develop or occlusion of the graft occurs. 6. Most thrombosed grafts can be reopened and should be explored promptly through an incision near the venous end.

Entities:  

Mesh:

Year:  1975        PMID: 1155732     DOI: 10.1016/0002-9610(75)90368-2

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  5 in total

1.  Subcutaneous brachial vein arteriovenous fistula for chronic hemodialysis.

Authors:  P G Koontz; T S Helling
Journal:  World J Surg       Date:  1983-09       Impact factor: 3.352

2.  A self-sealing dialysis prosthesis. Coaxial double PTFE-silicone graft.

Authors:  H Schanzer; G P Martinelli; G Bock; E C Peirce
Journal:  Ann Surg       Date:  1986-11       Impact factor: 12.969

3.  Experience with dacron graft arteriovenous fistulas for dialysis access.

Authors:  J F Burdick; W Scott; A B Cosimi
Journal:  Ann Surg       Date:  1978-03       Impact factor: 12.969

4.  Dacron velour arteriovenous fistula for hemodialysis access.

Authors:  S M Lindenauer; R Williams
Journal:  Ann Surg       Date:  1981-01       Impact factor: 12.969

5.  Aggressive approach to late thrombosis of bovine heterografts.

Authors:  P J Garvin; J E Codd
Journal:  Ann Surg       Date:  1979-12       Impact factor: 12.969

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.